ArticleBlood advances2022
The CLL comorbidity index in a population-based cohort: a tool for clinical care and research.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.European journal of haematology · 2026Pooled it
- How to assess multimorbidity: a systematic review.Frontiers in public health · 2025Pooled it
- Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study.Journal of cancer survivorship : research and practice · 2025Trial
- Article
- Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged ≥ 80 Years.European journal of haematology · 2026Review
- Hypertension affects survival and treatment in chronic lymphocytic leukemia.Blood advances · 2026Article
- Fitness in CLL.Cancers · 2026Review
- Chronic lymphocytic leukemia: criteria for first-line therapeutic choice-an opinion paper.Medical oncology (Northwood, London, England) · 2025Review
- Polypharmacy independently predicts survival, hospitalization, and infections in patients with lymphoid cancer.HemaSphere · 2025Article
- Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort.BMC cancer · 2024Article
- Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.JCO clinical cancer informatics · 2024Article
- Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives.Frontiers in immunology · 2024Review
- TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.Haematologica · 2023Article
- The Five "Ws" of Frailty Assessment and Chronic Lymphocytic Leukemia: Who, What, Where, Why, and When.Cancers · 2023Review
- First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era.Cancers · 2023Review
- A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.Blood advances · 2023Article
- A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale.Blood advances · 2023Article
- How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?Current oncology reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The chronic lymphocytic leukemia comorbidity index (CLL-CI) is an efficient, CLL-specific tool derived from the Cumulative Illness Rating Scale. The CLL-CI is based on the assessment of the organ systems found to be most strongly associated with event-free survival (EFS) in CLL: vascular, upper gastrointestinal, and endocrine, at the time of initiation of CLL therapy. The CLL-CI categorizes patients into low, intermediate, and high risk groups. In the present study, we have employed the CLL-CI in a population-based cohort comprising 4975 patients with CLL. We demonstrate that CLL-CI retains prognostic significance in this large cohort and is associated with overall survival (OS) and EFS from time of first therapy. Furthermore, CLL-CI associates with OS, EFS, and time to first treatment from diagnosis independently of the CLL International Prognostic Index. These findings support the use of the CLL-CI both in research and in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.